All patients
dMMR PD-L1 < 1% PDL1 (CPS < 1) PDL1 (CPS >1) pMMR
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
endometrial cancer, anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 0.59 [0.42; 0.83]
DUO-E (durvalumab then durvalumab alone vs control arms), 2023 0.77 [0.56; 1.06]
KEYNOTE-775, 2023 0.65 [0.55; 0.77]
MITO END-3, 2023 1.13 [0.62; 2.06]
RUBY (part 1), 2023 0.69 [0.54; 0.89]
0.68 [0.60 ; 0.77 ] DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023, DUO-E (durvalumab then durvalumab alone vs control arms), 2023, KEYNOTE-775, 2023, MITO END-3, 2023, RUBY (part 1), 2023 5 6% 2,403 moderate not evaluable PFS (extension)detailed results KEYNOTE-775, 2023 0.56 [0.48; 0.66]
0.56 [0.48 ; 0.66 ] KEYNOTE-775, 2023 1 0% 827 NA not evaluable progression or deaths (PFS)detailed results DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 0.55 [0.43; 0.70]
DUO-E (durvalumab then durvalumab alone vs control arms), 2023 0.71 [0.57; 0.89]
KEYNOTE-775, 2023 0.56 [0.47; 0.66]
MITO END-3, 2023 0.78 [0.51; 1.19]
NRG-GY018_dMMR, 2023 0.30 [0.19; 0.48]
NRG-GY018_pMMR, 2023 0.54 [0.41; 0.71]
RUBY (part 1), 2023 0.64 [0.51; 0.80]
RUBY (part 2), 2024 0.60 [0.43; 0.83]
0.58 [0.51 ; 0.67 ] DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023, DUO-E (durvalumab then durvalumab alone vs control arms), 2023, KEYNOTE-775, 2023, MITO END-3, 2023, NRG-GY018_dMMR, 2023, NRG-GY018_pMMR, 2023, RUBY (part 1), 2023, RUBY (part 2), 2024 8 50% 2,641 low not evaluable objective responses (ORR)detailed results KEYNOTE-775, 2023 2.97 [2.12; 4.18]
2.97 [2.12 ; 4.18 ] KEYNOTE-775, 2023 1 0% 827 NA not evaluable AE (any grade)detailed results DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 0.50 [0.02; 15.07]
KEYNOTE-775, 2023 2.10 [0.19; 23.24]
NRG-GY018_dMMR, 2023 0.51 [0.05; 5.70]
NRG-GY018_pMMR, 2023 1.01 [0.51; 1.98]
RUBY (part 1), 2023 0.98 [0.02; 49.57]
0.99 [0.54 ; 1.82 ] DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023, KEYNOTE-775, 2023, NRG-GY018_dMMR, 2023, NRG-GY018_pMMR, 2023, RUBY (part 1), 2023 5 0% 2,520 low not evaluable AE (grade 3-4)detailed results MITO END-3, 2023 0.61 [0.29; 1.28]
0.61 [0.29 ; 1.28 ] MITO END-3, 2023 1 0% 122 NA not evaluable AE (grade 3-5)detailed results DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 1.59 [1.09; 2.31]
KEYNOTE-775, 2023 3.26 [2.19; 4.85]
NRG-GY018_dMMR, 2023 1.93 [1.12; 3.33]
NRG-GY018_pMMR, 2023 1.48 [1.06; 2.07]
RUBY (part 1), 2023 1.61 [1.11; 2.35]
1.87 [1.40 ; 2.50 ] DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023, KEYNOTE-775, 2023, NRG-GY018_dMMR, 2023, NRG-GY018_pMMR, 2023, RUBY (part 1), 2023 5 63% 2,520 low not evaluable AE leading to death (grade 5)detailed results MITO END-3, 2023 4.10 [0.18; 92.86]
NRG-GY018_dMMR, 2023 0.22 [0.02; 2.51]
NRG-GY018_pMMR, 2023 3.02 [0.60; 15.11]
RUBY (part 1), 2023 10.40 [0.57; 191.46]
2.12 [0.46 ; 9.79 ] MITO END-3, 2023, NRG-GY018_dMMR, 2023, NRG-GY018_pMMR, 2023, RUBY (part 1), 2023 4 38% 1,318 low not evaluable AE leading to treatment discontinuation (any grade)detailed results DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 1.41 [0.90; 2.19]
KEYNOTE-775, 2023 7.41 [4.88; 11.26]
RUBY (part 1), 2023 2.05 [1.19; 3.52]
2.79 [0.97 ; 8.04 ] DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023, KEYNOTE-775, 2023, RUBY (part 1), 2023 3 94% 1,755 low not evaluable SAE (any grade)detailed results KEYNOTE-775, 2023 2.94 [2.20; 3.94]
RUBY (part 1), 2023 1.59 [1.08; 2.33]
2.19 [1.20 ; 4.00 ] KEYNOTE-775, 2023, RUBY (part 1), 2023 2 84% 1,281 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-25 14:18 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 77,383
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563
